Stevens Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Stevens Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-15,971	Closed	-$63K	–	1134
2017 Q1	$63K	Buy	+15,971	New	+$80.1K	﹤0.01%	828
2015 Q4	–	Sell	-21,830	Closed	-$183K	–	1205
2015 Q3	$183K	Buy	+21,830	New	+$348K	0.01%	846

Other funds holding SRNE

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Stevens Capital Management's SRNE Position: Q2 2017 in Review

Stevens Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2017, closing a stake of 15,971 shares — an estimated $63K sold.

Stevens Capital Management first reported a position in SRNE in Q3 2015 and held it in 2 quarters. The position peaked at $183K in Q3 2015. 46 funds tracked by Wall St. Rank hold SRNE as of Q2 2017.

Stevens Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Stevens Capital Management sold 15,971 Sorrento Therapeutics, Inc. shares in Q2 2017, an estimated $63K.
Stevens Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q3 2015 and held it in 2 quarters.
Stevens Capital Management's Sorrento Therapeutics, Inc. position peaked at $183K in Q3 2015.
46 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2017.

Based on Stevens Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.